Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer

BACKGROUND AND OBJECTIVES: Olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-α (PDGFRα). In a randomized phase II study, olaratumab plus doxorubicin met its predefined primary endpoint for progression-free survival and achieved a highly signi...

Descripción completa

Detalles Bibliográficos
Autores principales: Mo, Gary, Baldwin, John R., Luffer-Atlas, Debra, Ilaria, Robert L., Conti, Ilaria, Heathman, Michael, Cronier, Damien M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814542/
https://www.ncbi.nlm.nih.gov/pubmed/28620891
http://dx.doi.org/10.1007/s40262-017-0562-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814542/
https://www.ncbi.nlm.nih.gov/pubmed/28620891
http://dx.doi.org/10.1007/s40262-017-0562-0

Ejemplares similares